Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US0029421007
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG01223DLB2
AARD
Aardvark Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Software - Application · THEMEFOLIO: $HLTH
NAME
Aardvark Therapeutics Inc
ISIN
US0029421007
TICKER
AARD
MIC
XNAS
REUTERS
AARD.OQ
BLOOMBERG
AARD US
Mo., 24.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement")...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 23.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 22.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement")...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 22.08.2026       Aardvark Therapeutics
US0029421007

San Francisco, California--(Newsfile Corp. - August 21, 2026) - Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documen...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 21.08.2026       Aardvark Therapeutics
US0029421007

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) common stock between February 10, 2025 and May 14, 2026, inclusive (the “Class Period”). Aardvark investors have until October 1...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 21.08.2026       Aardvark Therapeutics
US0029421007

The DJS Law Group reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) violations of the federal securities laws.Shareholders who purchased shares of AARD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointme...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 21.08.2026       Aardvark Therapeutics
US0029421007

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a deadline is coming up on October 31, 2026, in the lawsuit that was filed for certain investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD). Investors, who purchased shares in excess of $100,...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

A securities class action alleges Aardvark Therapeutics overstated ARD-101's safety profile; Wall Street price targets collapsed from as high as $29 to $7 after the Phase 3 HERO trial was paused and the FDA imposed a clinical hold.NEW YORK, Aug. 20, 2026 /PRNewswire/ -- SueWallSt tracks the reversal in Wall Street analyst opinion on Aardvark Thera...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers. This lawsuit seeks to...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 20, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

Levi & Korsinsky, LLP notifies institutional investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between February 13, 2025 and May 14, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and certain officers and directors.   The class action, filed in the United States District Court for the Southern District of California, and docketed under 26-...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Aug. 20, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

Law Offices of Howard G. Smith announces an investigation on behalf of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK THERAPEUTICS, INC. (AARD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       Aardvark Therapeutics
US0029421007

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 19.08.2026       Aardvark Therapeutics
US0029421007

The Law Offices of Frank R. Cruz announces an investigation of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON AARDVARK THERAPEUTICS, INC. (AARD), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PU...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 19.08.2026       Aardvark Therapeutics
US0029421007

San Francisco, California--(Newsfile Corp. - August 19, 2026) - Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documen...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 19.08.2026       Aardvark Therapeutics
US0029421007

A securities class action alleges former Chief Operating Officer Bryan Jones, Ph.D. told investors in May 2025 that ARD-101 had a "very, very clean" safety profile, months before cardiac observations allegedly forced a Phase 3 pause and a full FDA clinical hold.NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 19.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Stateme...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 18.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 18, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 18.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired: (a) Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) common stock pursuant and/or traceable to the Offering D...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 18.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 18.08.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Aug. 18, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 17.08.2026       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 17, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b)...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 17.08.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospec...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 17.08.2026       Aardvark Therapeutics
US0029421007

Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 17.08.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) on behalf of investors that purchased or otherwise acquired Aardvark common stock pursuant and/or traceable to the Company's in...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 17.08.2026       Aardvark Therapeutics
US0029421007

Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 16.08.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 15.08.2026       Aardvark Therapeutics
US0029421007

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.07.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, July 30, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset....
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.07.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset....
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 25.06.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperpha...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 19.06.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, June 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperpha...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       Aardvark Therapeutics
US0029421007

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2026       Aardvark Therapeutics
US0029421007

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphag...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 22.05.2026       Aardvark Therapeutics
US0029421007

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphag...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphag...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       Aardvark Therapeutics
US0029421007

ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, April 22, 2026 /PRNewswire/ - On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperpha...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 10.04.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, April 10, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperph...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Aardvark Therapeutics
US0029421007

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       Aardvark Therapeutics
US0029421007

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Aardvark Therapeutics
US0029421007

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NYSE: AARD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Aardvark Therapeutics
US0029421007

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NYSE: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 28.02.2026       Aardvark Therapeutics
US0029421007

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or f...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink